https://orcid.org/0000-0002-5838-5607
References
- US Food and Drug Administration. Scientific considerations in demonstrating biosimilarity to a reference product: guidance for industry. 2015. https://www.fda.gov/media/82647/download
- European Medicines Agency. Guideline on similar biological medicinal product. 2014. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-rev1_en.pdf
- Kvien TK, Patel K, Strand V. The cost savings of biosimilars can help increase patient access and lift the financial burden of health care systems. Semin Arthritis Rheum. 2022;52:151939. doi: 10.1016/j.semarthrit.2021.11.009
- US Food and Drug Administration. Prolia: clinical pharmacology and biopharmaceutics review(s). 2010. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/125320s000clinpharmr.pdf
- Haraya K, Tsutsui H, Komori Y, et al. Recent advances in translational pharmacokinetics and pharmacodynamics prediction of therapeutic antibodies using modeling and simulation. Pharmaceuticals (Basel). 2022;15(5):508. doi: 10.3390/ph15050508
- Ait-Oudhia S, Ovacik MA, Mager DE. Systems pharmacology and enhanced pharmacodynamic models for understanding antibody-based drug action and toxicity. MAbs. 2017;9(1):15–28. doi: 10.1080/19420862.2016.1238995
- Sohn W, Simiens MA, Jaeger K, et al. The pharmacokinetics and pharmacodynamics of denosumab in patients with advanced solid tumours and bone metastases. A systemic review. Br J Clin Pharmacol. 2014;78(3):477–487. doi: 10.1111/bcp.12355
- Bekker PJ, Holloway DL, Rasmussen AS, et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res. 2004;19(7):1059–1066. doi: 10.1359/JBMR.040305
- Shi S. Biologics: an update and challenge of their pharmacokinetics. Curr Drug Metab. 2014;15(3):271–290. doi: 10.2174/138920021503140412212905
- Lewiecki EM, Miller PD, McClung MR, et al. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J Bone Miner Res. 2007;22(12):1832–1841. doi: 10.1359/jbmr.070809
- McClung MR, Lewiecki EM, Cohen SB, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med. 2006;354(8):821–831. doi: 10.1056/NEJMoa044459
- Miller PD, Bolognese MA, Lewiecki EM, et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone. 2008;43(2):222–229. doi: 10.1016/j.bone.2008.04.007
- Eastell R, Christiansen C, Grauer A, et al. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. J Bone Miner Res. 2011;26(3):530–537. doi: 10.1002/jbmr.251
- Williams C, Sapra A Osteoporosis markers. StatPearls [Internet] 2023. https://www.ncbi.nlm.nih.gov/books/NBK559306/
- US Food and Drug Administration. Prolia: Prescribing Information. 2023. https://www.pi.amgen.com/-/media/Project/Amgen/Repository/pi-amgen-com/prolia/prolia_pi.pdf